On the occasion of its quarterly publication, Eli Lilly announced that it was raising its annual target range for adjusted EPS by $1.30, to $13.50 to $14, and for revenues by $2 billion, to between $42.4 and $43.6 billion.

For the first three months of 2024, the pharmaceutical company posted a 59% increase in adjusted EPS (non-GAAP) to $2.58, including $0.10 in acquired intellectual property charges.

At $8.77 billion, sales were up 26% (of which 10% in volume growth and 16% in price increases), driven by its flagship drugs Mounjaro, Zepbound, Verzenio and Jardiance.

Copyright (c) 2024 CercleFinance.com. All rights reserved.